A provincial trial is set to begin in Alberta to investigate the effectiveness of hydroxychloroquine, a drug normally used for treating malaria, as a potential treatment for COVID-19.
It will aim to see if the drug could help people most at risk of severe symptoms from the novel coronavirus. The Alberta Hope COVID-19 study will recruit 1,600 at-risk Albertans to determine whether taking a five-day treatment of hydroxychloroquine (HCQ) lowers their hospitalization rates. “We will be targeting Albertans who are at risk of developing a severe case of COVID-19,” University of Calgary’s Dr.
Luanne Metz, who is leading the study, said in a news release Monday. [ Sign up for our Health IQ newsletter for the latest coronavirus updates ] “Those